As early as the establishment of Berry Gene in 2010, Zhou Daixing had the idea of ​​entering the field of cancer. Berry's gene starts from non-invasive detection of chromosomal diseases, and naturally it also thinks about the expansion of single-gene disease. The team began researching single-gene disease detection technology, the later Circulating Single-Molecule Amplification and Resequencing Technology (cSMART).

When the technical team discovered that the technology could detect very low levels of free fetal DNA mutations from maternal blood, they realized that cSMART technology can be applied to non-invasive detection of tumors and is quite feasible.

In 2013, the Berry Gene Oncology Division was formally established. Subsequently, Onconi tumor molecular diagnostic products, one of the core technologies of cSMART, were launched.

This is the beginning of Berry's gene tumor business and the origin of the Swiss gene. Based on this product, Berry's gene has extended a series of products including drug guidance and efficacy monitoring in the middle and late stage, and laid a solid foundation for the company.

The first detection application of angkeyi is liquid detection of non-small cell lung cancer targeted drugs, because the targeted genes of non-small cell lung cancer are well studied and clinically familiar with specific gene mutations and drug relationships.

After the establishment of the Cancer Division, Berry Gene has successively launched testing products such as gynecological tumors and colorectal cancer. With the independence of the Cancer Division into the Swiss-German gene, they officially opened the early screening project and began to expand from the advanced tumor detection to early warning screening.

昂科益 is a series of tumor molecular diagnostic products based on international and domestic patented cSMART technology and deeply optimized PCR amplicon sequencing technology (tPAS detection), which has covered non-small cell lung cancer, colorectal cancer, Research and application of all solid tumor-targeted drug therapy and immunotherapy for solid tumor whole target gene detection and hereditary tumor detection.

The proprietary CSMART technology developed by Berry Gene captures a very low percentage of ctDNA fragments in the blood, enabling absolute quantification of gene mutation detection. At the same time, the company relies on the full interpretation of its own Chinese population database and international advanced database to enable doctors and patients to obtain accurate and easy-to-understand test reports.

Not only that, in the laboratory of Berry's genes, the upgrade of technology has never stopped. Through further innovation, the upgraded cSMART 2.0 technology not only maintains all the advantages of the original cSMART technology in terms of sample size and sensitivity, but also achieves a significant increase in the number of genes and the utilization of sequencing data in blood testing. There has also been a substantial increase.

Angkor is also a comprehensive tumor detection product based on high-throughput sequencing, which can accurately detect multiple mutations such as SNV, Indel and Fusion. Tumors are a type of genetic disease. Currently, there are at least 140 driving genes associated with tumorigenesis. A typical tumor cell usually carries 2-8 gene mutations. Angkyi can detect multiple genes, multiple sites, multiple mutation types simultaneously, and can detect hundreds of tumor-related genes with 10ml of venous blood.

With the exploration and discovery of tumor pathogenesis, genotyping directly affects the therapeutic effect of tumors has become an increasingly clear cognition in the industry: genetic differences in patients may cause different patients to produce different or even opposite drugs for the same drug. The therapeutic effect. In the case of targeted therapy for non-small cell lung cancer, gefitinib has a good effect on patients with positive mutations in EGFR gene sensitivity, but not well in patients with drug resistance mutations.

Therefore, for the treatment of cancer patients, pre-medication genetic testing is essential. Based on accurate detection of the patient's genetic level, doctors can give more accurate medication guidance.

As a member of the Berry Gene, Herui Gene has obtained an exclusive license for its tumor-related technology patents and product services in mainland China. This is not only the integration and convergence of its tumor business, but also gives the Swiss gene a fairly high starting point.

Start the early screening project, gradually covering by point and face

In August 2017, Berry Gene initiated the establishment of the Swiss Gene, which undertook all oncology businesses. At the end of the same year, Herui Gene raised RMB 800 million in one lump sum. Soon after, their long-awaited early tumor screening research was officially voiced.

On April 22, 2018, Herui Gene announced that it has jointly launched a national multi-center, prospective liver cancer early warning screening project with the National Hepatocellular Science Center/Shanghai Oriental Hepatobiliary Surgery Hospital and Guangzhou Nanfang Hospital. This is the first and only ongoing prospective cohort study of ultra-large-scale liver cancer early screening in China, which marks a solid first step in the development of the early-warning early-diagnosis business.

Prior to this, the pilot test of the Swiss gene has been initiated. At the same time that the project was announced, they have accumulated a large amount of data related to early diagnosis of tumors, completed the comprehensive construction of the technology platform, and initially established a multi-omics experimental program and classification markers and analysis algorithms for early screening of liver cancer. It laid the foundation for a large-scale prospective cohort study.

At the same time, Ruirui revealed that in the next three years, the company will have more tumor early diagnosis research projects released, gradually covering more tumors from point to point.

As a member company hatched from Berry's gene, Werui Gene has undertaken Berry's career and vision for cancer prevention and treatment.

At the same time, in the initial stage, the technology, capital and team provided by Berry Gene and all the shareholders also make the company different. The company has more abundant resources and is also responsible for solving tumors nationwide and even globally. The mission of genetic testing, especially early diagnosis of cancer, is a century-long problem.

This is reminiscent of the relationship between Illumina and Grail. It is also the industry leader background, research and development of tumor early screening technology, and the introduction of investment from the parent company. He Rui Gene and Grail started almost at the same time, and now they are conducting large-scale prospective clinical trials, and look forward to the early realization of the dream of early diagnosis of cancer.

Two companies with high starting points are destined to be concerned by the industry and expected by the industry. However, unlike Grail, the company's mature mid-to-late stage tumor detection products are being tested in the market while providing significant market information and advanced tumor data. It is believed that in the near future, they will promote the widespread application of early tumor early screening technology in clinical practice, and realize the good wishes of “all early tumor diagnosis and treatment, accurate treatment of all patients”.

Biochemical Pharmaceuticals

Injectable Insulin,Glutathione Lyophilized,Equine Tetanus Antitoxin,Tetanus Antitoxin Injection

NINGBO VOICE BIOCHEMIC CO. LTD , https://www.medicine-voice.com